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two Methylentetrahydrofolate Reductase (MTHFR)
polymorphisms in esophagogastric cancer: the
A1298C MTHFR polymorphism is an independent
prognostic factor only in neoadjuvantly treated
gastric cancer patients
Susanne Blank1†, Sivaramakrishna Rachakonda2†, Gisela Keller3, Wilko Weichert4, Florian Lordick5, Rupert Langer6,
Christoph Springfeld7, Thomas Bruckner8, Karen Becker3, Rajiv Kumar2† and Katja Ott1*†Abstract
Background: Methylentetrahydrofolate reductase (MTHFR) plays a major role in folate metabolism and
consequently could be an important factor for the efficacy of a treatment with 5-fluorouracil. Our aim was to
evaluate the prognostic and predictive value of two well characterized constitutional MTHFR gene polymorphisms
for primarily resected and neoadjuvantly treated esophagogastric adenocarcinomas.
Methods: 569 patients from two centers were analyzed (gastric cancer: 218, carcinoma of the esophagogastric
junction (AEG II, III): 208 and esophagus (AEG I): 143). 369 patients received neoadjuvant chemotherapy followed
by surgery, 200 patients were resected without preoperative treatment. The MTHFR C677T and A1298C
polymorphisms were determined in DNA from peripheral blood lymphozytes. Associations with prognosis, response
and clinicopathological factors were analyzed retrospectively within a prospective database (chi-square, log-rank,
cox regression).
Results: Only the MTHFR A1298C polymorphisms had prognostic relevance in neoadjuvantly treated patients but it
was not a predictor for response to neoadjuvant chemotherapy. The AC genotype of the MTHFR A1298C
polymorphisms was significantly associated with worse outcome (p = 0.02, HR 1.47 (1.06-2.04). If neoadjuvantly
treated patients were analyzed based on their tumor localization, the AC genotype of the MTHFR A1298C
polymorphisms was a significant negative prognostic factor in patients with gastric cancer according to UICC 6th
edition (gastric cancer including AEG type II, III: HR 2.0, 95% CI 1.3-2.0, p = 0.001) and 7th edition (gastric cancer
without AEG II, III: HR 2.8, 95% CI 1.5-5.7, p = 0.003), not for AEG I. For both definitions of gastric cancer the AC
genotype was confirmed as an independent negative prognostic factor in cox regression analysis. In primarily
resected patients neither the MTHFR A1298C nor the MTHFR C677T polymorphisms had prognostic impact.
(Continued on next page)* Correspondence: katja.ott@med.uni-heidelberg.de
†Equal contributors
1Department of Surgery, University Hospital of Heidelberg, Im Neuenheimer
Feld 110, Heidelberg 69120, Germany
Full list of author information is available at the end of the article
© 2014 Blank et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Blank et al. BMC Cancer 2014, 14:58 Page 2 of 15
http://www.biomedcentral.com/1471-2407/14/58(Continued from previous page)
Conclusions: The MTHFR A1298C polymorphisms was an independent prognostic factor in patients with
neoadjuvantly treated gastric adenocarcinomas (according to both UICC 6th or 7th definitions for gastric cancer) but
not in AEG I nor in primarily resected patients, which confirms the impact of this enzyme on chemotherapy
associated outcome.
Keywords: Esophagogastric adenocarcinoma, Prognostic factors, Folate metabolism, Methylentetrahydrofolate
reductase, Genetic polymorphisms, C677T, A1298CBackground
Multimodal treatment is the standard of care for locally
advanced adenocarcinomas of the esophagus or stomach
since several randomized trials and meta-analyses have
shown a prognostic benefit for (peri-) preoperative therapy
versus surgery alone [1-4]. For patients who received
multimodal treatment it is widely accepted that respond-
ing patients have a significantly better outcome than non-
responding patients [5-8]. However, depending on the
therapy regimen applied, only 25-50% of patients respond
to (peri-) preoperative treatment. Until now no molecular
markers are available to predict response or survival in
clinical routine and to tailor treatment individually. Des-
pite the current guidelines favoring a multimodal treat-
ment for locally advanced tumors, a relevant number of
patients are still resected without preoperative treatment
due to favorable tumor categories, differing local stan-
dards, individual risk factors or patients’ choice.
Simple pretherapeutically available cliniocopathological
factors like tumor localization, grading, content of signet
ring cells and Laurén classification have been found to be
associated with prognosis in patients with and without pre-
operative treatment in several studies [9-14]. So far, how-
ever these factors are not routinely used to tailor treatment
or to stratify groups within clinical trials. Several studies
on molecular and genetic prognostic and/or predictive
markers in patients with gastric cancer have been pub-
lished, but none of them (apart from HER-2 [15] in the pal-
liative setting) gained clinical relevance [16,17]. Aside from
tumor related factors, constitutional factors such as genetic
polymorphisms are accepted to be associated with re-
sponse and prognosis in adenocarcinomas of esophagus or
stomach [18-21]. Most data exist for genetic polymor-
phisms being involved in pharmacodynamics and drug me-
tabolism. Our own data on constitutional polymorphisms
have shown to a large extent that the examined constitu-
tional variants were associated rather with prognosis, than
with response to preoperative treatment [22,23]. Only a
few studies have investigated constitutional factors with
the goal to clarify whether these factors are only relevant in
the presence of chemotherapy or if they are prognostic fac-
tors irrespective of preoperative treatment [22].
Methylentetrahydrofolate reductase (MTHFR) plays a
major role in the folate metabolism and consequentlycould be an important factor for the efficacy of a treat-
ment with 5-fluorouracil (5-FU) [24-27].
The MTHFR single nucleotide polymorphism (SNP)
C677T (rs 1801133) has shown to be associated with
prognosis in gastric cancer patients in several studies
[23,28,29], however results are still conflicting [30] and
the clinical relevance of this SNP has to be reproduced
before clinical consequences can be drawn.
Another SNP in the MTHFR gene (A1298C) (rs
1801131) has also been investigated in several studies
but results are less convincing than for C677T [31,32].
A recent study of our group found a significant associ-
ation of this MTHFR gene A1298C polymorphism with
prognosis in 258 neoadjuvantly treated esophagogastric
adenocarcinomas [23].
In this study we focused on these two polymorphisms
in the MTHFR gene to confirm the prognostic signifi-
cance of the respective MTHFR gene polymorphisms in
a larger group of esophagogastric cancer patients with
neoadjuvant treatment as well as to test whether these
polymorphisms can be used as a predictor for response
to neoadjuvant chemotherapy. Additionally we wanted
to test their relevance in a group of patients without
perioperative chemotherapy.
Methods
569 patients with histologically proven adenocarcinoma
of the esophagus (AEG I), esophagogastric junction
(AEG II, III) or stomach (GC) were included in the
study. Patients were treated in the Klinikum rechts der
Isar, Munich from 1994–2005 (n = 361) or the Univer-
sity Hospital Heidelberg, Surgical Department from
2007–2010 (n = 235), 27 patients were excluded due to
non-operative treatment. 369 patients received neoad-
juvant chemotherapy followed by surgery, while 200
patients were resected without preoperative treatment
(Figure 1).
It is of note that for 244 of the 369 neoadjuvantly treated
patients the results with shorter follow-up have been re-
ported recently for both analyzed polymorphisms [23].
The study was approved by the ethical committee
of the University of Heidelberg and of the Technical
University of Munich and written informed consent was
obtained from all patients.
Figure 1 Flow chart.
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Demographic data, primary tumor localization, grading,
type of resection, Lauren’s subtype, ypTNM- and R-
category, data on clinical and histopathological response
as well as perioperative complications and mortality
were documented prospectively in a database containing
all patients with carcinoma of the esophagus or stomach
in the two centers.
Genotyping
Blood was collected from patients before surgery. DNA
from blood was isolated with Qiagen mini-preparation kits
and genotyped for the two polymorphisms in the MTHFR
gene (C677T and A1298C). Genotyping was performed
using KASPar chemistry, a competitive allele-specific PCR
genotyping system (http://www.lgcgenomics.com) accord-
ing to manufacturer’s instructions. The PCR was carried
out in plates of 96 wells, in a total reaction volume of 8 μl
using 10 ng of genomic DNA, 2 μl 2X KASPar reaction
mix and 0.11 μl of the assay mix. The PCR conditions
were: an initial denaturation at 94°C for 15 minutes, 10
touch-down cycles of 20 s at 94°C and 60 s at 61-55°C
(temperature decrement by 0.6°C per cycle) and additional
25–30 cycles at 20 s at 94°C and 60 s at 55°C. Genotypes
in amplified products were determined by differences in
VIC and FAM fluorescent level in plate read operation on
ABI PRISM 7900HT (Applied Biosystems, Foster City,
CA) using SDS 2.2 Software. Post operation data were
transferred to Microsoft Excel files and converted into
genotype information. The genotype quality control was
validated through DNA sequencing in 5% of the samples.
Chemotherapy
369 patients were treated with neoadjuvant chemotherapy:
Munich (n = 247): OLF/PLF regimen: either oxaliplatin
85 mg/m2 or cisplatin 50 mg/m2 on days 1,15,29 and
folinic acid (500 mg/m2 over 2 h) plus fluorouracil
(2000 mg/m2) on days 1,8,15,22,29 and 36, all repeated
on day 49, for patients with a good health statusadditionally paclitaxel (80 mg/m2) on days 0, 14 and
28) was given [33]. Heidelberg (n = 122): EOX-regimen:
epirubicin 50 mg/m2 (day 1), oxaliplatin 130 mg/m2
(day 1), and capecitabin 1,250 mg/m2 (days 1–21), all
repeated on day 22., PLF (see above), and FLOT: oxalipla-
tin 85 mg/m2 (day 1), docetaxel 50 mg/m2 (day 1), folina-
cid 200 mg/m2 (day 1), and 5-fluoruracil 2,600 mg/m2
(day 1), all repeated on day 15 [9].
Surgery
The type of surgery was performed according to the
tumor localization and local standards: for patients with
AEG I either an abominothoracic approach with intra-
thoracic anastomosis (Ivor Lewis procedure) [34] or a
transhiatal esophagectomy [35], both including an ab-
dominal D-2 lymphadenectomy, for patients with adeno-
carcinoma of the esophagogastric junction (AEG II, III)
a transhiatal gastrectomy, in some cases an Ivor lewis
procedure [36] or a transhiatal esophagectomy [35] was
performed. Patients with gastric cancer received a total
gastrectomy or subtotal gastrectomy [37] if an adequate
proximal resection margin was possible. Both proce-
dures included a D2-lymphadenectomy.
Response to chemotherapy
Clinical response was assessed after chemotherapy and
before surgery comparing pre- and posttherapeutic
computed tomography imaging and endoscopy. The
evaluation was done by an interdisciplinary tumor
board of the Klinikum rechts der Isar, Munich or by
the Surgical Department of the University of Heidel-
berg. Criteria for response were a decrease of the max-
imal transversal tumor diameter of >50% in CT and an
estimated decrease in endoluminal tumor size of >75%
in endoscopy. Patients with minor response, no change
or progressive disease were classified as nonresponder
[38-40].
Histopathological response was assessed according to
the Becker regression score [5,41]: tumor regression
Table 1 Patients’ characteristics and survival times according to clinicopathological factors
Characteristics n % Median (months) 3-Y-S (%) 5-Y-S (%) p
a: All patients
Sex Male 431 75.7 66.0 60.8 52.6 0.637
Female 138 24.3 66.0 57.0 52.7
Localization AEG 351 61.7 74.2 60.4 52.4 0.81
UICC 7th edition Gastric cancer 212 37.3 62.2 58.7 52.3
Localization AEG I 143 25.1 108.0 63.0 55.5 0.288
UICC 6th edition AEG II/III + GC 426 74.9 64.1 58.9 51.8
Laurén intestinal 320 56.2 78.8 65.1 57.2 0.029
non-intestinal 234 41.1 47.1 54.8 48.2
Grading low grade 166 29.2 108.0 69.3 64.7 0.012
high grade 395 69.4 54.1 56.4 47.8
pT pT0 38 6.7 n.r. 85.6 76.4 <0.001
pT1 52 9.1 n.r. 83.5 83.5
pT2 276 48.5 85.6 68.7 62.5
pT3 184 32.2 26.7 37.4 25.4
pT4 19 3.3 14.2 5.3 0.0
pN pN0 242 42.5 101.9 76.8 69.6 <0.001
pN1 201 35.3 33.3 48.2 39.4
pN2 74 13 26.3 41.3 34.6
pN3 28 4.9 18.9 25.4 25.4
pNx 24 4.2 n.r. 78.5 78.5
pM pM0 525 92.3 72.8 62.0 54.6 0.001
pM1 44 7.7 23.6 36.3 32.2
R R0 476 83.7 74.2 64.7 56.7 <0.001
R1/R2 93 16.3 20.3 34.2 32.2
Neoadjuvant chemotherapy yes 369 64.9 74.2 61.5 52.6 0.157
no 200 35.1 62.2 56.8 53.1
Characteristics n % Median (months) 3-Y-S (%) 5-Y-S (%) p
b: Neoadjuvantly treated patients
Sex Male 309 83.7 78.8 63.2 53.7 0.253
Female 60 16.3 48.6 53.0 46.9
Localization AEG 287 77.8 78.8 63.4 54.4 0.259
UICC 7th edition Gastric cancer 82 22.2 42.5 55.7 46.3
Localization AEG I 139 37.7 108.0 62.8 55.3 0.653
UICC 6th edition AEG II/III + GC 230 62.3 66.0 61.0 51.1
Laurén Intestinal 220 59.6 108.0 67.3 58.7 0.014
Non-intestinal 140 37.9 40.5 54.4 44.6
Grading Low grade 109 29.5 108.0 73.0 68.2 0.008
High grade 254 68.8 47.1 56.8 45.3
pT pT0 38 10.3 n.r. 85.6 76.4 <0.001
pT1 35 9.5 n.r. 83.2 83.2
pT2 169 45.8 101.9 68.7 60.3
pT3 116 31.4 26.9 39.5 25.2
pT4 11 3.0 14.2 0.0 0.0
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Table 1 Patients’ characteristics and survival times according to clinicopathological factors (Continued)
pN pN0 157 42.5 108.0 77.4 69.3 <0.001
pN1 142 38.5 34.0 49.0 38.6
pN2 39 10.6 29.1 44.1 31.6
pN3 17 4.6 18.9 38.5 38.5
pNx 14 3.8 n.r. 77.9 77.9
pM pM0 328 88.9 82.7 65.1 55.6 <0.001
pM1 41 11.1 23.6 33.4 28.6
R R0 291 78.9 n.r. 69.0 58.4 <0.001
R1/R2 78 21.1 20.3 32.7 30.4
Clinical response Responder 105 28.5 39.2 82.6 74.2 <0.001
Nonresponder 263 71.3 108.0 52.4 42.8
TRG 1a,1b 104 28.2 n.r. 83.8 77.4 <0.001
2,3 263 71.3 39.2 52.5 42.1
Characteristics n % Median (months) 3-Y-S (%) 5-Y-S (%) p
c: Primarily resected patients
Sex Male 122 61.0 62.2 54.6 50.1 0.318
Female 78 39.0 66.0 60.5 57.5
Localization AEG 64 32.0 32.6 46.9 44.3 0.049
UICC 7th edition Gastric cancer 131 65.5 64.1 60.7 56.4
Localization AEG I 4 2.0 n.r. 75.0 75.0 0.619
UICC 6th edition AEG II/III + GC 196 98.0 62.2 56.5 52.9
Laurén Intestinal 100 50.0 62.2 59.8 53.4 0.807
Non-intestinal 94 47.0 64.1 55.7 54.0
Grading Low grade 57 28.5 62.2 61.5 55.9 0.526
High grade 141 70.5 64.1 55.8 52.2
pT pT0 0 0.0 <0.001
pT1 17 8.5 n.r. 86.5 86.5
pT2 107 53.5 85.6 68.5 65.4
pT3 68 34.0 25.8 33.2 26.6
pT4 8 4.0 10.3 12.5 12.5
pN pN0 85 42.5 85.6 76.0 70.2 <0.001
pN1 59 29.5 32.0 45.4 41.6
pN2 35 17.5 21.7 37.9 28.4
pN3 11 5.5 16.1 9.1 9.1
pNx 10 5.0 n.r. 78.8 78.8
pM pM0 197 98.5 62.2 56.6 52.9 0.684
pM1 3 1.5 n.r. 66.7 66.7
R R0 185 92.5 64.1 57.8 53.9 0.144
R1/R2 15 7.5 18.1 44.4 0.0
MS =median survival, 3-Y-S = 3-Year-Survival, 5-Y-S = 5-Year-Survival, AEG = adenocarcinoma of the esophagogastric junction, TRG = tumor regression grade,
n.r. = not reached.
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sidual tumor) were classified as histopathological re-
sponse, TRG 2 (10-50% residual tumor) and 3 (>50%
residual tumor) as nonresponse.Follow-up
Follow-up was done according to the local guidelines.
Patients who were not followed in one of the two cen-
ters were contacted by phone to obtain follow-up data.
Table 2 Genotype frequencies: MTHFR C677T
MTHFR C677T p
CC CT TT
All patients 254 (44.6%) 262 (46.0%) 53 (9.3%)
Status Alive 143 (42.2%) 162 (47.8%) 34 (10%) 0.342
Dead 111 (48.3%) 100 (43.5%) 19 (8.3%)
Sex Male 189 (43.9%) 202 (46.9%) 40 (9.3%) 0.775
Female 65 (47.1%) 60 (43.5%) 13 (9.4%)
Localization AEG 153 (43.6%) 169 (48.1%) 29 (8.3%) 0.337
UICC 7th edtiion Gastric cancer 99 (46.7%) 90 (42.5%) 23 (10.8%)
Localization AEG I 63 (44.1%) 68 (47.6%) 12 (8.4%) 0.868
UICC 6th edition AEG II/III + GC 191 (44.8%) 194 (45.5%) 41 (9.6%)
Laurén Intestinal 137 (42.8%) 151 (47.2%) 32 (10.0%) 0.731
Non-intestinal 107 (45.7%) 107 (45.7%) 20 (8.5%)
Grading Low grade 74 (44.6%) 75 (45.2%) 17 (10.2%) 0.89
High grade 174 (44.1%) 185 (46.8%) 36 (9.1%)
pT pT0 14 (36.8%) 21 (55.3%) 3 (7.9%) 0.751
pT1 20 (38.5%) 28 (53.8%) 4 (7.7%)
pT2 134 (48.6%) 118 (42.8%) 24 (8.7%)
pT3 78 (42.4%) 86 (46.7%) 20 (10.9%)
pT4 8 (42.1%) 9 (47.4%) 2 (10.5%)
pN pN0 109 (45.0%) 115 (47.5%) 18 (7.4%) 0.642
pN1 93 (46.3%) 88 (43.8%) 20 (10.0%)
pN2 31 (41.9%) 33 (44.6%) 10 (13.5%)
pN3 12 (42.9%) 15 (53.6%) 1 (3.6%)
pNx 9 (37.5%) 11 (45.8%) 4 (16.7%)
pM pM0 236 (45.0%) 243 (46.3%) 46 (8.8%) 0.292
pM1 18 (40.9%) 19 (43.2%) 7 (15.9%)
R R0 213 (44.7%) 218 (45.8%) 45 (9.5%) 0.948
R1/R2 41 (44.1%) 44 (47.3%) 8 (8.6%)
Neoadjuvant chemotherapy yes 161 (43.6%) 179 (48.5%) 29 (7.9%) 0.135
no 93 (46.5%) 83 (41.5%) 24 (12.0%)
Clinical response Responder 44 (41.9%) 52 (49.5%) 9 (8.6%) 0.885
Nonresponder 117 (44.5%) 126 (47.9%) 20 (7.6%)
TRG 1a,1b 44 (42.3%) 53 (51.0%) 7 (6.7%) 0.783
2,3 116 (44.1%) 125 (47.5%) 22 (8.4%)
AEG = adenocarcinoma of the esophagogastric junction, GC = gastric cancer, TRG = tumor regression grade.
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41.1+/− 25.8 months.
Statistical analysis
For statistical analysis we used SPSS 20.0 (IBM Inc.
Chicago). Quantitative data is presented as mean +/−
standard deviation. Survival curves were estimated by the
Kaplan-Meier method and presented in months from time
of diagnosis to death. Differences in survival times were
calculated using the log-rank test. For univariate andmultivariate analysis we used the Cox proportional hazard
model. For correlation between different parameters we
used the Chi-square-test (two-sided) where appropriate.
P-values <0.05 were considered as statistically significant.
Results
230 patients out of 569 have died. Median survival of
the entire population was 66.0 months. Median survival
of patients treated in Munich was 72.8 months, in Hei-
delberg 85.6 months.
Table 3 Genotype frequencies: MTHFR A1298C
MTHFR A1298C p
AA AC CC
All patients 244 (42.9%) 268 (47.1%) 54 (9.5%)
Status Alive 152 (45.1%) 149 (44.2%) 36 (10.7%) 0.162
Dead 92 (40.2%) 119 (52.0%) 18 (7.9%)
Sex Male 184 (43.0%) 204 (47.1%) 40 (9.3%) 0.945
Female 60 (43.5%) 64 (46.4%) 14 (10.1%)
Localization AEG 152 (43.7%) 164 (47.1%) 32 (9.2%) 0.793
UICC 7th edtition Gastric cancer 87 (41.0%) 103 (48.6%) 22 (10.4%)
Localization AEG I 60 (42.6%) 68 (48.2%) 13 (9.2%) 0.968
UICC 6th edition AEG II/III + GC 184 (43.3%) 200 (47.1%) 41 (9.6%)
Laurén Intestinal 140 (44.0%) 150 (47.2%) 28 (8.8%) 0.835
Non-intestinal 100 (42.9%) 109 (46.8%) 24 (10.3%)
Grading Low grade 70 (42.4%) 77 (46.7%) 18 (10.9%) 0.76
High grade 172 (43.8%) 186 (47.3%) 35 (8.9%)
pT pT0 16 (42.1%) 18 (47.4%) 4 (10.5%) 0.701
pT1 17 (33.3%) 28 (54.9%) 6 (11.8%)
pT2 119 (43.3%) 125 (45.5%) 31 (11.3%)
pT3 83 (45.4%) 88 (48.1%) 12 (6.6%)
pT4 9 (47.4%) 9 (47.4%) 1 (5.3%)
pN pN0 98 (40.7%) 118 (49.0%) 25 (10.4%) 0.654
pN1 97 (48.5%) 84 (42.0%) 19 (9.5%)
pN2 30 (41.1%) 37 (50.7%) 6 (8.2%)
pN3 9 (32.1%) 16 (57.1%) 3 (10.7%)
pNx 10 (41.7%) 13 (54.2%) 1 (4.2%)
pM pM0 226 (43.3%) 244 (46.7%) 52 (10.0%) 0.402
pM1 18 (40.9%) 24 (54.5%) 2 (4.5%)
R R0 199 (42.0%) 226 (47.7%) 49 (10.3%) 0.239
R1/R2 45 (48.9%) 42 (45.7%) 5 (5.4%)
Neoadjuvant chemotherapy Yes 156 (42.6%) 179 (48.9%) 31 (8.5%) 0.4
No 88 (44.0%) 89 (44.5%) 23 (11.5%)
Clinical response Responder 46 (43.8%) 49 (46.7%) 10 (9.5%) 0.812
Nonresponder 109 (41.9%) 130 (50.0%) 21 (8.1%)
TRG 1a,1b 41 (39.4%) 55 (52.9%) 8 (7.7%) 0.628
2,3 114 (43.8%) 123 (47.3%) 23 (8.8%)
AEG = adenocarcinoma of the esophagogastric junction, GC = gastric cancer, TRG = tumor regression grade.
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presented in Table 1.
Relevant prognostic factors were Laurén’s type (p = 0.029),
Grading (p = 0.012), (y)pT-category (p < 0.0000001), (y)
pN-category (p < 0.0000001), (y)pM-category (p = 0.001),
R-category (p < 0.0000001), additionally clinical response
(p < 0.0000001) and histopathological response (p < 0.0000001)
for patients treated with neoadjuvant chemotherapy.Genotype frequencies and correlation with
clinicopathological factors
The genotype frequencies were in accordance with the
Hardy-Weinberg-equilibrium. Frequencies of the indi-
vidual genotypes are presented in Tables 2 and 3. No in-
dividual genotype showed any statistical correlation with
a clinicopathological factor listed above, also if analyzed
separately for the respective tumor entities (AEG versus
Table 4 Survival according to the individual genotypes
n MS (months) p HR (95% CI)
a: All patients
MTHFR C677T CC 254 54.1 0.412
CT 262 82.7 0.88 (0.67-1.15)
TT 53 n.r. 0.75 (0.46-1.22)
CC 254 54.1 0.237
CT + TT 315 82.7 0.86 (0.66-1.11)
MTHFR A1298C AA 244 82.7 0.036
AC 268 47.1 1.31 (1.0-1.72)
CC 54 74.2 0.77 (0.47-1.28)
AC 268 47.1 0.016
AA + CC 301 82.7 0.73 (0.56-0.94)
n MS (months) p HR (95% CI)
b: Neoadjuvantly treated patients
MTHFR C677T CC 161 55.4 0.745
CT 179 82.7 0.98 (0.7-1.38)
TT 29 n.r. 0.77 (0.4-1.51)
CC 161 55.4 0.77
CT + TT 208 82.7 0.95 (0.69-1.32)
MTHFR A1298C AA 156 101.9 0.063
AC 179 47.1 1.43 (1.02-2.01)
CC 31 74.2 0.85 (0.44-1.67)
AC 179 47.1 0.02
AA + CC 190 101.9 0.68 (0.49-0.94)
n MS (months) p HR (95% CI)
c: Primarily resected patients
MTHFR C677T CC 93 54.1 0.295
CT 83 n.r. 0.72 (0.45-1.15)
TT 24 66.0 0.69 (0.34-1.4)
CC 93 54.1 0.119
CT + TT 107 66.0
MTHFR A1298C AA 88 66.0 0.366
AC 89 47.6 0.16 (0.74-1.82)
CC 23 62.2 0.68 (0.31-1.46)
AC 89 47.6 0.295
AA + CC 111 66.0 0.79 (0.52-1.22)
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neoadjuvant treatment).
Genotypes and survival
Survival and type of treatment
Survival analysis was conducted for the whole study co-
hort as well as for neoadjuvantly and primarily resected
patients separately. The MTHFR C677T polymorphisms
did not show a statistically significant influence onsurvival times in all patients (p = 0.412) nor in any ana-
lyzed subgroup (in neoadjuvantly treated patients p =
0.745, in primarily resected patients p = 0.295), although
there was a slight trend for shorter survival of patients
with the CC genotype (54.1 months median in patients
with CC genotype versus 82.7 months in patients with
CT and TT genotype, p = 0.237), Table 4a.
In contrast, the MTHFR A1298C polymorphisms were
prognostically relevant (p = 0.036) in all patients. The
Figure 2 Survival in gastric cancer patients according to UICC 6th edition, MTHFR A1298C. Legend: Subgroup analysis for patients with
adenocarcinoma of the esophagogastric junction type II, III and stomach dependent on polymorphisms of MTHFR A1298C. Median Survival times:
AA 101.9 months, CC 74.2 months, AC 35.0 months, p = 0.005.
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http://www.biomedcentral.com/1471-2407/14/58AC genotype was associated with a worse outcome com-
pared to AA and CC. As we did not find a prognostic
difference between the AA and CC genotype, the two
homozygous genotypes were combined and analyzed to-
gether: 47.1 months median for AC genotype versus
82.7 months for AA/CC genotype, p = 0.016, see Table 4a.Figure 3 Survival in gastric cancer patients according to UICC 6th edi
for patients with adenocarcinoma of the esophagogastric junction type II, I
comparing AC genoytpe to AA and CC genotype. Median Survival times: AThe prognostic effect of MTHFR A1298C might be
caused by the neoadjuvant treatment as it could not be
shown in primarily resected patients.
The survival of the neoadjuvantly treated and pri-
marily resected patients are presented in detail in
Table 4b and c. In neoadjvuantly treated patients thetion, MTHFR A1298C AC versus AA/CC. Legend: Subgroup analysis
II and stomach dependent on polymorphisms of MTHFR A1298C,
A/CC 82.7 months, AC 35.0 months, p = 0.001).
Figure 4 Survival in gastric cancer patients according to UICC 7th edition, MTHFR A1298C. Legend: Subgroup analysis for patients with
adenocarcinoma of the stomach dependent on polymorphisms of MTHFR A1298C. Median Survival times: AA 82.7 months, CC not reached, AC
26.5 months, p = 0.009.
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http://www.biomedcentral.com/1471-2407/14/58A1298C polymorphisms showed a survival benefit for
the AA and CC genotypes, compared to the AC
genotype (p = 0.02). In primarily resected patients the
polymorphisms of both gene loci were not different
in survival.Figure 5 Survival in gastric cancer patients according to UICC 7th edi
for patients with adenocarcinoma of the stomach dependent on polymorp
genotype. Median Survival times: AA/CC not reached, AC 26.5 months, p =Survival in respect of tumor localization
Furthermore, the association of the respective genotypes
with prognosis was tested stratified for the different
tumor localizations. In primarily resected patients we
found no correlation between MTHFR polymorphismstion, MTHFR A1298C AC versus AA/CC. Legend: Subgroup analysis
hisms of MTHFR A1298C, comparing AC genoytpe to AA and CC
0.002.
Table 5 Multivariate analysis in neoadjuvantly treated
patients with gastric cancer including AEG II, III (UICC 6th)
HR 95% CI p
pT pT0 1.00 0.002
pT1 2.16 0.2-20.8
pT2 5.10 0.7-37.5
pT3 9.80 1.3-74.3
pT4 14.50 1.7-122.9
R R0 1.00 0.001
R1/2 2.20 1.3-3.5
Clinical response yes 1.00 0.026
no 2.10 1.1-4.2
MTHFR A1298C AA 1.00 0.01
AC 2.00 1.3-3.2
CC 1.49 0.7-3.3
Blank et al. BMC Cancer 2014, 14:58 Page 11 of 15
http://www.biomedcentral.com/1471-2407/14/58and prognosis for the different localizations. In neoadju-
vantly treated patients both polymorphisms had no
prognostic impact in adenocarcinomas of the esophagus
(AEG I) nor if taken all junctional tumors (AEG I, II, III)
together according to the UICC 7th classification. This
is in contrast to patients with adenocarcinoma of the
stomach: according to the old classification (gastric can-
cer including AEG II, III, UICC 6th) (Figures 2 and 3) as
well as in gastric cancer according to the new classifica-
tion (gastric cancer without AEG II, III, UICC 7th) the
MTHFR A1298C polymorphism was a prognostic factor
(p = 0.005 and 0.009 respectively), (Figures 4 and 5). The
AC genotype had a significantly worse prognosis com-
pared to the rest in gastric cancer defined by the
UICC6th (p = 0.001, HR 2.0 (1.3-3.0)) and the UICC 7th
(p = 0.003, HR 2.8 (1.5-5.7)).
Multivariate analysis
In neoadjuvantly treated gastric cancer patients accord-
ing to UICC 6th edition multivariate analysis (forward
proportional hazard model) (including the univariateTable 6 Multivariate Analysis in neoadjuvantly treated
patients with gastric cancer without AEG II, III (UICC 7th)
HR 95% CI p
R R0 1.00 0.001
R1/2 3.40 1.7-6.8
Clinical response yes 1.00 0.021
no 10.30 1.4-75.5
MTHFR A1298C AA 1.00 0.028
AC 2.80 1.3-5.9
CC 2.00 0.5-7.6significant factors grading, pT-, pN-category, R-category,
clinical and histopathological response, MTHFR A1298C
polymorphisms as well as gender and age for adjust-
ment) revealed pT-category (p = 0.002), R-category
(p = 0.001), clinical response (p = 0.026) and MTHFR
A1298C (p = 0.01) as independent prognostic factors. In
gastric cancer patients according to UICC 7th edition
(including grading, pT-category, R-category, clinical re-
sponse and MTHFR A1298C polymorphisms as well as
gender and age) R-category (p = 0.001), clinical response
(p = 0.021) and MTHFR A1298C (p = 0.028) were identi-
fied as independent prognostic factors (Tables 5 and 6).
All prognostic factors were confirmed by the backward
proportional hazard model.
Discussion
Our study revealed the AC genotype of the MTHFR
A1298C as a predictor of poor prognosis in patients with
gastric cancer. However, this genotype was only a prog-
nostic marker after neoadjuvant treatment not in pri-
marily resected patients. This gives a clear hint towards
the contribution of the chemotherapy on the prognostic
impact of this polymorphism. Additionally the prognos-
tic influence seems to be limited to gastric cancer (UICC
6th or 7th edition) since it was not apparent for adeno-
carcinomas of the esophagus.
Both examined MTHFR polymorphisms are known
to be functionally relevant. The variants (CT and TT)
of MTHFR C677T polymorphisms are associated with
decreased activity of MTHFR, which results in higher
homocystein levels and lower plasma folate levels [42,43].
Similarly, the A1298C variants (AC and CC) are associ-
ated with a lower enzyme activity, but results in literature
are less final and conclusive than for C677T [31,32,44].
Our findings on MTHFR C677T are not statistically
significant, but the trend for longer survival of the vari-
ants of C677T (CT and TT) would be in line with the
functional hypothesis.
Furthermore MTHFR is thought to play an important
role in response to fluoropyrimidine containing chemo-
therapy. A decreased activity of MTHFR results in higher
5,10-methylene tetrahydrofolate levels which leads to
inhibition of thimidylate synthase and consequently to
DNA damage [45-47] leading theoretically to an increased
response and survival. This simplified theoretical ap-
proach cannot be confirmed by our data. Our results are
in part conflicting, which points out the complexity of
chemotherapy response and prognosis. Both seem to be
affected by multiple pathways and related polymorphisms.
In our study the AC variant of MTHFR A1298C is neither
associated with response nor with improved outcome, but
with poor prognosis in the subgroup of neoadjuvantly
treated patients. However there exists data in literature,
which correspond to our findings on the MTHFR A1298C
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http://www.biomedcentral.com/1471-2407/14/58polymorphism. Locally advanced adenocarcinoma of
the stomach treated with cisplatin and 5-FU based chemo-
therapy with the variants of MTHFR A1298C (AC, CC)
were associated with higher risks of recurrence and death
in gastric cancer patients in a recent paper from our group
[23] including 244 identical patients. Another study in-
cluding unresectable, advanced gastric carcinomas re-
ported similar results with shorter survival times of
A1298C variants (AC and CC) (6.6 months median sur-
vival versus 18.5 months of the wild type (AA), p = 0.001)
[48]. A pathway driven approach including amongst
others both MTHFR polymorphisms showed conflicting
results for esophageal cancer compared to ours. Longer
survival and recurrence-free survival times could be
shown for the MTHFR A1298C variants types (p = 0.01)
as well as for combination of variant alleles at both loci
(AC +CC) compared to the individuals with one wild type
allele (AA) [49]. Two other studies reported a survival
benefit for the TT variant of C677T [28,50] in patients
with fluorouracil-based chemotherapy. In the adjuvant
setting the CC genotype of MTHFR C677T was associated
with shorter recurrence-free survival (p = 0.031) [28].
However, several other studies could not show any prog-
nostic impact of one the MTHFR polymorphisms for pa-
tients with esophagogastric cancer [22,51-53], so that
results remain controversial (see Table 7).
As in our previous published studies [16,22,23] we
could not show an association between the two poly-
morphisms and response to neoadjuvant treatment.Table 7 MTHFR polymorphisms in literature
Author Year Polymorphism n Treatment Tumor entity
Ott [22] 2006 MTHFR C677T 235 neo CTx 135 AEGII/III/GC
OP 103 AEGII/III/GC
Ott [23] 2011 MTHFR C677T 258 neo CTx AEGI 114
AEGII-GC 144
MTHFR A1298C 258 neo CTx AEGI 114
AEGII-GC 144
Huang [28] 2008 MTHFR C677T 116 adj CTx GC
Wu [49] 2006 MTHFR C677T 210 neoCTx/RCTx AEGI 174/SCC
MTHFR A1298C 210 neoCTx/RCTx AEGI 174/SCC
Ruzzo [51] 2006 MTHFR C677T 175 pall CTx GC
Chen [48] 2010 MTHFR A1298C 16/73 pall CTx GC
Lu [54] 2004 MTHFR C677T 75 pall CTx GC
Goekkurt [52] 2009 MTHFR C677T 134 pall CTx AEG/GC
MTHFR A1298C 134 pall CTx AEG/GC
Goekkurt [55] 2006 MTHFR C677T 52 pall CTx GC
Shitara [50] 2010 MTHFR C677T 132 pall CTx GC
Lee [53] 2005 MTHFR C677T 40 adj CTx GC
neo = neoadjuvant, CTx = chemotherapy, RCTx = radiochemotherapy, OP = primarily
esophagus/esophagusgastric junction, GC = gastric cancer, n.s. = not significant, n.a.Most of the studies on MTHFR polymorphisms and
upper gastrointestinal cancer could not reproduce the
association of response with fluoropyrimidine based
chemotherapy having been described for other cancer
types, mainly advanced colon carcinoma [45,56,57],
apart from one Chinese study for the TT genotype of the
MTHFR C677T polymorphism and response [54].
In one study including metastatic gastroesophageal
adenocarcinomas, the AC variant of MTHFR A1298C
was associated with lower response rates (27% responder
in contrast to 48 and 46% responder for AA and CC
genotype, p = 0.053) [52]. Other studies could not con-
firm the effect of MTHFR C677T and A1298C variants
in response to chemotherapy [22,23,51] (see Table 7).
The conflicting and heterogenous findings highlight
the demand on comprehensive pathway-based approaches
for the prediction of response and prognosis by genetic
polymorphisms as a potentially more successful and
promising strategy. Beside the activity of the MTHFR, also
the individual folate intake might influence outcome. Indi-
viduals with a high dietary folate intake are described to
have a lower risk of developing gastrointestinal cancer.
Consequently not only MTHFR polymorphisms, which
play an important role in folate metabolism but also folate
intake could be associated with prognosis in patients with
esophagogastric carcinoma [50].
Further general problems of the presented studies are
their heterogeneity and lack of comparability with re-
spect to the number of patients included, inclusionResponse (p-value) Prognosis (p-value) Genotypes In P F
0.14 0.14
- 0.23
n.s. n.s.
n.s. n.s.
n.s. n.s.
n.s. 0.02 AA > CC > AC yes
0.04 TT/CT > CC 0.056
36 n.a. n.s.
36 n.a. 0.011 AC/CC > AA n.a.
0.2 n.s.
- <0.001 AA > AC/CC n.a.
0.001 - TT > CC/CT <0.001
0.214 0.319
0.053 0.524
0.099 n.s.
n.a. 0.039 TT > CC/CT
0.90
resected, adj = adjuvant, pall = palliative, AEG = adenocarcinoma of the
= not applied, In P F = independent prognostic factor.
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http://www.biomedcentral.com/1471-2407/14/58criteria (type of tumor, tumor stage), different treatment
concepts (palliative treatment versus curative treatment
including radical surgery) and different genotypes. The
change from UICC 6th to 7th might especially complicate
the comparability of old and recent studies, as AEG II
and III are classified differently [58]. To exclude this bias
we repeated the analyses for both classifications and
could show that in patients with AEG I or adenocarcin-
omas of the esophagogastric junction, the MTHFR poly-
morphisms did not have prognostic impact related to
our recent paper [23].
Our study has some limitations. The first limitation is
the inclusion of patients, on which we already reported
recently, however, the follow-up was significantly ex-
tended [22,23]. Secondly it is a retrospective exploratory
study and therefore has the typical disadvantages of this
study type.
But in contrast to many other studies, we analyzed
patients being primarily resected without perioperative
concepts to evaluate the prognostic impact of the de-
scribed polymorphisms apart from response to chemo-
therapy as a simple prognostic factor. In our study
the prognostic impact of MTHFR A1298C could not
be demonstrated in primarily resected patients. This
leads to the conclusion that response to treatment
plays an important role for influence on survival of the
different genotypes, despite the effect on response
could not be measured by a correlation with clinical
and histopathological response in this study. A further
strength of our study is the relatively high number
of patients, to our knowledge the largest published
series, the inclusion of adenocarcinomas only and a
homogenous 5-FU containing preoperative treatment
followed by resection.
Conclusions
The AC genotype of the MTHFR A1298C was associ-
ated with a poor prognosis in neoadjuvantly treated gas-
tric cancer patients, although there was no association
with clinically or histopathologically assessed response
to chemotherapy. This gives a clear hint towards the
modulation of prognosis by chemotherapy, which cannot
be measured by the available methods of response evalu-
ation. Large patient numbers and pathway driven ap-
proaches seem necessary to evaluate the prognostic
impact of polymorphisms in patients with esophagogas-
tric adenocarcinomas to tailor treatment in the future.
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